AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listing, of claims in the application.

Listing of Claims

1. (original) A compound represented by Formula I or Formula II





I II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

m is 0, 1, 2 or 3,

n is 0, 1 or 2;

–A–B–C–D– is selected from the group consisting of:

(1) –CH_2–CH_2–CH_2–O–,

(2) –CH_2–CH_2–C(O)–O–,

(3) –CH=CH–C(O)–O–,

(4) –O–CH_2–CH_2–CH_2–,

(5) –O–C(O)–CH_2–CH_2–,

(6) –HC=CH–CH_2–O–,

(7) –CH_2–HC=CH–O–,

(8) –CH_2–CH_2–C(O)–NH–,

(9) –CH_2–NH–CH_2–CH_2–,

(10) –CH_2–NH–C(O)–O–,

(11) –NH–C(O)–NH–C(O)–,

(12) –C(O)–NH–C(O)–NH–,
(13) –NH–C(O)–NH–CH_2–,
(14) –NH–C(O)–NH–C(=S)–,
(15) –O–CH_2–CH_2–O–,
(16) –S-CH_2-CH_2-S-;

provided that when the atoms at positions B and C of –A–B–C–D– are both carbon atoms, said atoms may be joined together to form a ring selected from



X and Y are each independently selected from CH_2, S and O;

R^1 is selected from the group consisting of:
(1) $C_{1\text{-}6}$alkyl,
(2) $C_{2\text{-}6}$alkenyl,
(3) $C_{2\text{-}6}$akynyl,
(4) $C_{3\text{-}6}$cycloalkyl,
(5) aryl,
(6) -CH_2-phenyl,
(7) HET,

wherein items (1) to (3) above are optionally substituted from one to three substituents independently selected from the group consisting of: halo, OR^5, and NHR^6, and items (4) to (7) are optionally substituted with from one to three substituents selected from the group consisting of: halo, OR^5, NHR^6, $C_{1\text{-}3}$alkyl, $C_{2\text{-}6}$alkenyl, $C_{2\text{-}6}$akynyl;

R^2 and R^3 are each independently selected from the group consisting of:

(1) hydrogen,
(2) halo,
(3) C_{1-6}alkyl,
(4) C_{2-6}alkenyl,
(5) C_{2-6}akynyl,
(6) OR^7,
(7) NHR^8,
(8) aryl,
(9) $-CH_2$-phenyl;

R^5, R^6, R^7 and R^8 are each independently selected from the group consisting of:

(1) hydrogen,
(2) methyl;

each R^4 is independently selected from the group consisting of

(1) -OH,
(2) $-C_{1-6}$alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, =S, and halo,
(3) C_{2-6}alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and –C(O)-O- C_{1-2}alkyl,
(4) C_{2-6}alkynyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy and halo,
(5) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C_{1-2}alkyl, -COOH, $-C(O)-O-CH_3$ and halo,
(6) $-C_{1-2}$alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C_{1-2}alkyl and halo,
(7) $-CO_2H$,
(8) $-CO_2C_{1-3}$alkyl,
(9) $-OC_{1-3}$alkyl,
(10) $-SO_2-C_{1-3}$alkyl,
(11) $-SO_2$-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C_{1-2}alkyl and halo
(12) $-C_{1-2}$alkyl-O-C_{1-2}alkyl,
(13) $-C_{1-2}$alkyl-O-C_{2-4}alkenyl,
(14) $-C_{1-2}$alkyl-O-phenyl optionally substituted with with 1, 2 or 3 substituents independently selected from hydroxy, C_{1-2}alkyl and halo,

(15) -C_{1-2}alkyl-C(O)O-C_{1-2}alkyl,

(16) 2-(1,3-dioxan)ethyl,

(17) -C_{1-2}alkyl-C(O)-NH-phenyl,

(18) -C_{1-2}alkyl-C(O)-NHN.

2. (original) A compound according to claim 1 wherein m is 0, 1 or 2.

3. (original) A compound according to claim 1 wherein n is 0 or 1.

4. (original) A compound according to claim 1 wherein R^2 and R^3 are each individually hydrogen or methyl.

5. (original) A compound according to claim 1 wherein each R^4 is independently selected from the group consisting of

(1) -OH,

(2) -C_{1-6}alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, thio, and halo,

(3) C_{2-6}alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and –C(O)-O- C_{1-2}alkyl,

(4) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C_{1-2}alkyl, -COOH, -C(O)-O-CH_3 and halo,

(5) -C_{1-2}alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C_{1-2}alkyl and halo,

(6) -SO_2-C_{1-3}alkyl, and

(7) -C_{1-2}alkyl-OC_{1-2}alkyl.

6. (original) A compound according to Claim 1 wherein R^1 is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

(a) halo,

(b) OCH_3,

(d) CH_3,

(e) CN.

7. (original) A compound according to Claim 6 wherein R^1 is phenyl, optionally mono or di-substituted with halo.

8. (original) A compound of Formula I according to claim 1



I

Wherein

m is 0, 1, 2 or 3;

n is 0 or 1;

R^1 is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

(a) halo,

(b) OCH_3,

(d) CH_3,

(e) CN; and

R^2 and R^3 are each individually hydrogen or methyl.

9. (original) A compound according to claim 8 wherein

Each R^4 is independently selected from the group consisting of

(1) -OH,

(2) -C_{1-6}alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, thio, and halo,

(3) C_{2-6}alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and –C(O)-O- C_{1-2}alkyl,

(4) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C_{1-2}alkyl, -COOH, -C(O)-O-CH_3 and halo,

(5) -C_{1-2}alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C_{1-2}alkyl and halo,

(6) -SO_2-C_{1-3}alkyl, and

(7) -C_{1-2}alkyl-OC_{1-2}alkyl.

10. (original) A compound according to claim 9 wherein

–A–B–C–D– is selected from the group consisting of:

(1) –CH_2–CH_2–CH_2–O–,

(2) –CH=CH– CH_2–O–,

(3) – CH_2-CH=CH–O–,

(4) –O–CH_2–CH_2–CH_2–,

(5) –O–CH_2–CH_2–O–,

(6) –S–CH_2–CH_2–S–,

(7) –CH_2–NH–CH_2–CH_2–, and

(8) –CH_2–NH–C(O)–O–;

R^1 is phenyl optionally mono or di- substituted with halo.

11. (original) A compound of Formula II according to claim 1



II

Wherein

m is 0, 1 or 2;

n is 0 or 1;

R^1 is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

(a) halo,

(b) OCH_3,

(d) CH_3,

(e) CN; and

R^2 and R^3 are each individually hydrogen or methyl.

12. (original) A compound according to claim 11 wherein

Within this genus, there is a sub-genus of compounds wherein

each R^4 is independently selected from the group consisting of $-C_{1-6}$alkyl or hydrogen.

13. (original) A compound according to claim 11 wherein

X and Y are both O or are both S or X is O and Y is CH_2;

R^1 is phenyl optionally mono or di- substituted with halo.

14. (original) A compound according to claim 1 selected from the group consisting of




OH
O
N
N
F


O
O
N
N
F

O
O
N
N
F


O
N
N
F


O
N
N
F




O
N
N
F


O
N
N
F


O
N
N
F


O
N
N
F










O
O
N
N
F
O
O
N
N
F
O
O
N
N
F
O
N
N
F



15. (original) A compound according to claim 1 of the formula



k	R
1	Vinyl
1	Phenyl
1	4-fluorophenyl
2	Benzyl
2	Vinyl
2	Ethyl

16. (original) A compound according to claim 1 of the formula



k	D	A	C	Ra	Rb
1	O	CH_2	CH_2	propyl	Propyl
1	O	CH_2	CHOH	propyl	Propyl
1	O	CH_2	CH_2	allyl	Allyl
1	O	CH_2	CHOH	allyl	Allyl
1	O	CH_2	CH_2	methyl	Methyl

1	O	CH_2	CHOH	methyl	Methyl
1	O	CH_2	C(O)	methyl	Methyl
1	O	CH_2	CH_2	H	H
1	O	CH_2	CHOH	H	H
2	CH_2	O	CH_2	ethyl	H
2	CH_2	O	CH_2	H	Ethyl
2	CH_2	O	CH_2	H	Phenyl
2	O	CH_2	CH(allyl)	allyl	Allyl
2	O	CH_2	CH_2	methyl	Methyl
2	O	CH_2	CH_2	benzyl	Benzyl
2	O	CH_2	CH_2	allyl	Allyl
2	O	CH_2	CHOH	methyl	Methyl
2	O	CH_2	CHOH	allyl	Allyl
2	O	CH_2	CH(allyl)	H	H
2	O	CH_2	C(O)	methyl	Methyl
2	O	CH_2	C(O)	allyl	Allyl

17. (original) A compound according to claim 1 of the formula
















HO
O
N
O
O
N
N
F


N
H
O
N
O
O
N
N
F


O
N
O
O
N
N
F












































O
O
N
N
F


O
O
N
N
F


O
O
N
N
F


O
O
N
N





18. (original) A compound of the formula



k	**R**
1	Phenyl
2	Ethyl
2	Phenyl

19. (original) A compound according to claim 1 of the formula



Ra
Methyl
Allyl
Isopropyl
2-methoxyethyl
CH_2CO_2Et
2-(1,3-dioxan)ethyl

20. (original) A compound of the formula



C_1	D_1	A_1	B_1
C(O)	NCH_3	C(O)	NH
NCH_2Ph	C(O)	NCH_3	C(O)
NCH_3	C(O)	NCH_3	C(O)
$NCH_2CH=CH_2$	C(O)	NCH_3	C(O)
C(O)	NCH_3	C(O)	NCH_2Ph

C(O)	NCH_3	C(O)	NCH_3
C(O)	NCH_3	C(O)	$NCH_2CH=CH_2$
C(O)	NCH_3	C(O)	NH
$N(CH_2)_2CO_2H$	C(O)	NCH_2Ph	C(O)
NH	C(O)	$N(CH_2)_2CO_2H$	C(O)
NH	C(O)		C(O)
C(O)	NCH_3	C(O)	$N(CH_2)_2CO_2H$
C(O)	NCH_3	C(O)	
$NCH_2CH=CH_2$	C(O)	$NCH_2CH=CH_2$	C(O)
NCH_2Ph	C(O)	NCH_2Ph	C(O)
NH	C(S)	NCH_2Ph	C(O)
NH	C(S)	NH	C(O)
NH	C(S)	$NCH_2CH=CH_2$	C(O)
NH	C(S)	NCH_3	C(O)
NH	CH_2	NCH_2Ph	C(O)
NH	CH_2	NH	C(O)
C(O)	NCH_3	CH_2	NCH_3
NH	CH_2	NCH_3	C(O)

21. (original) A compound according to claim 1 for the formula

















O
O
N
N
F

O
O
N
N
F


O
O
N
N
F






















O
O
N
N
F

O
O
N
N
F


Cl
Cl
O
O
N
N
F


Cl
Cl
O
O
N
N
F

O
O
O
O
N
N
F


O
O
O
O
N
N
F












O
O
N
N
F

O
O
N
N
F


O
O
N
N
F


O
O
N
N
F

O
O
N
N
F


O
O
O
N
N
F










O
O
N
N
F

O
O
N
N
F


O
O
N
N
F


O
O
N
N
F















O
O
N
N
F

O
O
N
N
F


MeO2C
CO2Me
O
O
N
N
F














S
S
N
N
F


O
O
N
N
F


O
O
N
N
F


O
O
N
N
F










O
O
N
N
F

O
O
N
N
F


O
O
N
N
F


O
O
N
N
F





















































22. (original) A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.

23. (original) A method for treating a glucocorticoid receptor mediated disease or condition in a mammalian patient in need of such treatment comprising administering the patient a compound according to claim 1 in an amount that is effective for treating the glucocorticoid receptor mediated disease or condition.

24.- 27. (cancel)